|
1
|
Adams JM and Cory S: The Bcl-2 protein
family: Arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Levine B, Sinha S and Kroemer G: Bcl-2
family members: Dual regulators of apoptosis and autophagy.
Autophagy. 4:600–606. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Opferman JT and Korsmeyer SJ: Apoptosis in
the development and maintenance of the immune system. Nat Immunol.
4:410–415. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zong WX, Lindsten T, Ross AJ, MacGregor GR
and Thompson CB: BH3-only proteins that bind pro-survival Bcl-2
family members fail to induce apoptosis in the absence of Bax and
Bak. Genes Dev. 15:1481–1486. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Inohara N, Gourley TS, Carrio R, Muñiz M,
Merino J, Garcia I, Koseki T, Hu Y, Chen S and Núñez G: Diva, a
Bcl-2 homologue that binds directly to Apaf-1 and induces
BH3-independent cell death. J Biol Chem. 273:32479–32486. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kang Y, Lee DC, Han J, Yoon S, Won M, Yeom
JH, Seong MJ, Ko JJ, Lee KA, Lee K and Bae J: NM23-H2 involves in
negative regulation of Diva and Bcl2L10 in apoptosis signaling.
Biochem Biophys Res Commun. 359:76–82. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mikata R, Yokosuka O, Fukai K, Imazeki F,
Arai M, Tada M, Kurihara T, Zhang K, Kanda T and Saisho H: Analysis
of genes upregulated by the demethylating agent
5-aza-2′-deoxycytidine in gastric cancer cell lines. Int J Cancer.
119:1616–1622. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ke N, Godzik A and Reed JC: Bcl-B, a novel
Bcl-2 family member that differentially binds and regulates Bax and
Bak. J Biol Chem. 276:12481–12484. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Naumann U, Weit S, Wischhusen J and Weller
M: Diva/Boo is a negative regulator of cell death in human glioma
cells. FEBS Lett. 505:23–26. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang H, Holzgreve W and De Geyter C:
Bcl2-L-10, a novel anti-apoptotic member of the Bcl-2 family,
blocks apoptosis in the mitochondria death pathway but not in the
death receptor pathway. Hum Mol Genet. 10:2329–2339. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoon SJ, Kim JW, Choi KH, Lee SH and Lee
KA: Identification of oocyte-specific diva-associated proteins
using mass spectrometry. Korean J Fertil Steril DE. 33:189–198.
2006.
|
|
12
|
Yoon SJ, Kim EY, Kim YS, Lee HS, Kim KH,
Bae J and Lee KA: Role of Bcl2-like 10 (Bcl2l10) in regulating
mouse oocyte maturation. Biol Reprod. 81:497–506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim EA, Kim KS, Lee HS, Lee S, Kim EY, Seo
YM, Bae J and Lee KA: Downstream genes regulated by Bcl2l10 RNAi in
the mouse oocytes. Dev Reprod. 15:61–69. 2011.
|
|
14
|
Lee SY, Kim EY, Kim KH and Lee KA:
Bcl2l10, a new Tpx2 binding partner, is a master regulator of
Aurora kinase A in mouse oocytes. Cell Cycle. 15:3296–3305. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Joukov V: Aurora kinases and spindle
assembly: Variations on a common theme? Cell Cycle. 10:895–903.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kufer TA, Silljé HH, Körner R, Gruss OJ,
Meraldi P and Nigg EA: Human TPX2 is required for targeting
Aurora-A kinase to the spindle. J Cell Biol. 158:617–623. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Giubettini M, Asteriti IA, Scrofani J, De
Luca M, Lindon C, Lavia P and Guarguaglini G: Control of Aurora-A
stability through interaction with TPX2. J Cell Sci. 124:113–122.
2011. View Article : Google Scholar
|
|
18
|
Giet R, Petretti C and Prigent C: Aurora
kinases, aneuploidy and cancer, a coincidence or a real link?
Trends Cell Biol. 15:241–250. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Compérat E, Camparo P, Haus R,
Chartier-Kastler E, Radenen B, Richard F, Capron F and Paradis V:
Aurora-A/STK-15 is a predictive factor for recurrent behaviour in
non-invasive bladder carcinoma: A study of 128 cases of
non-invasive neoplasms. Virchows Arch. 450:419–424. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lassmann S, Shen Y, Jütting U, Wiehle P,
Walch A, Gitsch G, Hasenburg A and Werner M: Predictive value of
Aurora-A/STK15 expression for late stage epithelial ovarian cancer
patients treated by adjuvant chemotherapy. Clin Cancer Res.
13:4083–4091. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nishida N, Nagasaka T, Kashiwagi K, Boland
CR and Goel A: High copy amplification of the Aurora-A gene is
associated with chromosomal instability phenotype in human
colorectal cancers. Cancer Biol Ther. 6:525–533. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jeng YM, Peng SY, Lin CY and Hsu HC:
Overexpression and amplification of Aurora-A in hepatocellular
carcinoma. Clin Cancer Res. 10:2065–2071. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Anand S, Penrhyn-Lowe S and Venkitaraman
AR: AURORA-A amplification overrides the mitotic spindle assembly
checkpoint, inducing resistance to Taxol. Cancer Cell. 3:51–62.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meraldi P, Honda R and Nigg EA: Aurora-A
overexpression reveals tetraploidization as a major route to
centrosome amplification in p53-/- cells. EMBO J.
21:483–492. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nikonova AS, Astsaturov I, Serebriiskii
IG, Dunbrack RL Jr and Golemis EA: Aurora A kinase (AURKA) in
normal and pathological cell division. Cell Mol Life Sci.
70:661–687. 2013. View Article : Google Scholar
|
|
26
|
Xu JD, Furuya T, Cao XX, Liu XL, Li QQ,
Wang WJ, Xu JW, Xu ZD, Sasaki K and Liu XP: Loss of BCL2L10 protein
expression as prognostic predictor for poor clinical outcome in
gastric carcinoma. Histopathology. 57:814–824. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu JD, Cao XX, Long ZW, Liu XP, Furuya T,
Xu JW, Liu XL, De Xu Z, Sasaki K and Li QQ: BCL2L10 protein
regulates apoptosis/proliferation through differential pathways in
gastric cancer cells. J Pathol. 223:400–409. 2011. View Article : Google Scholar
|
|
28
|
Mikata R, Fukai K, Imazeki F, Arai M,
Fujiwara K, Yonemitsu Y, Zhang K, Nabeya Y, Ochiai T and Yokosuka
O: BCL2L10 is frequently silenced by promoter hypermethylation in
gastric cancer. Oncol Rep. 23:1701–1708. 2010.PubMed/NCBI
|
|
29
|
Bai Y, Wang J, Han J, Xie XL, Ji CG, Yin
J, Chen L, Wang CK, Jiang XY, Qi W and Jiang HQ: BCL2L10 inhibits
growth and metastasis of hepatocellular carcinoma both in vitro and
in vivo. Mol Carcinog. 56:1137–1149. 2017. View Article : Google Scholar
|
|
30
|
Nougarede A, Popgeorgiev N, Kassem L,
Omarjee S, Borel S, Mikaelian I, Lopez J, Gadet R, Marcillat O,
Treilleux I, et al: Breast cancer targeting through inhibition of
the endoplasmic reticulum-based apoptosis regulator Nrh/BCL2L10.
Cancer Res. 78:1404–1417. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cluzeau T, Robert G, Mounier N, Karsenti
JM, Dufies M, Puissant A, Jacquel A, Renneville A, Preudhomme C,
Cassuto JP, et al: BCL2L10 is a predictive factor for resistance to
azacitidine in MDS and AML patients. Oncotarget. 3:490–501. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Carvajal RD, Tse A and Schwartz GK: Aurora
kinases: New targets for cancer therapy. Clin Cancer Res.
12:6869–6875. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fu J, Bian M, Jiang Q and Zhang C: Roles
of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res.
5:1–10. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW,
Sahin A, Brinkley BR and Sen S: Tumour amplified kinase STK15/BTAK
induces centrosome amplification, aneuploidy and transformation.
Nat Genet. 20:189–193. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
D’Andrilli G, Kumar C, Scambia G and
Giordano A: Cell cycle genes in ovarian cancer: Steps toward
earlier diagnosis and novel therapies. Clin Cancer Res.
10:8132–8141. 2004. View Article : Google Scholar
|
|
36
|
Gautschi O, Heighway J, Mack PC, Purnell
PR, Lara PN Jr and Gandara DR: Aurora kinases as anticancer drug
targets. Clin Cancer Res. 14:1639–1648. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Keen N and Taylor S: Aurora-kinase
inhibitors as anticancer agents. Nat Rev Cancer. 4:927–936. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou N, Singh K, Mir MC, Parker Y, Lindner
D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A and Hansel DE:
The investigational Aurora kinase A inhibitor MLN8237 induces
defects in cell viability and cell-cycle progression in malignant
bladder cancer cells in vitro and in vivo. Clin Cancer Res.
19:1717–1728. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li JP, Yang YX, Liu QL, Pan ST, He ZX,
Zhang X, Yang T, Chen XW, Wang D, Qiu JX and Zhou SF: The
investigational Aurora kinase A inhibitor alisertib (MLN8237)
induces cell cycle G2/M arrest, apoptosis, and autophagy via p38
MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Drug Des Devel Ther. 9:1627–1652. 2015.PubMed/NCBI
|
|
40
|
Görgün G, Calabrese E, Hideshima T, Ecsedy
J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, et al: A
novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and
cell-cycle arrest in multiple myeloma. Blood. 115:5202–5213. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Asteriti IA, Di Cesare E, De Mattia F,
Hilsenstein V, Neumann B, Cundari E, Lavia P and Guarguaglini G:
The Aurora-A inhibitor MLN8237 affects multiple mitotic processes
and induces dose-dependent mitotic abnormalities and aneuploidy.
Oncotarget. 5:6229–6242. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Komarova NL: Genomic instability in
cancer: Biological and mathematical approaches. Cell Cycle.
3:1081–1085. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang XD: Genome-wide screens for
effective siRNAs through assessing the size of siRNA effects. BMC
Res Notes. 1:332008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Collins K, Jacks T and Pavletich NP: The
cell cycle and cancer. Proc Natl Acad Sci USA. 94:2776–2778. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jones RG and Thompson CB: Tumor
suppressors and cell metabolism: A recipe for cancer growth. Genes
Dev. 23:537–548. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
del Rincón SV, Widschwendter M, Sun D,
Ekholm-Reed S, Tat J, Teixeira LK, Ellederova Z, Grolieres E, Reed
SI and Spruck C: Cks overexpression enhances chemotherapeutic
efficacy by overriding DNA damage checkpoints. Oncogene.
34:1961–1967. 2015. View Article : Google Scholar
|
|
48
|
Schwartz GK and Shah MA: Targeting the
cell cycle: A new approach to cancer therapy. J Clin Oncol.
23:9408–9421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Spano D, Heck C, De Antonellis P,
Christofori G and Zollo M: Molecular networks that regulate cancer
metastasis. Semin Cancer Biol. 22:234–249. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kang Y and Massague J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yao D, Dai C and Peng S: Mechanism of the
mesenchymal-epithelial transition and its relationship with
metastatic tumor formation. Mol Cancer Res. 9:1608–1620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Swanson WF, Roth TL and Wildt DE: In vivo
embryogenesis, embryo migration, and embryonic mortality in the
domestic cat. Biol Reprod. 51:452–464. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lamalice L, Le Boeuf F and Huot J:
Endothelial cell migration during angiogenesis. Circ Res.
100:782–794. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Luster AD, Alon R and von Andrian UH:
Immune cell migration in inflammation: Present and future
therapeutic targets. Nat Immunol. 6:1182–1190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Friedl P and Alexander S: Cancer invasion
and the microenvironment: Plasticity and reciprocity. Cell.
147:992–1009. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Friedl P and Wolf K: Tumour-cell invasion
and migration: Diversity and escape mechanisms. Nat Rev Cancer.
3:362–374. 2003. View Article : Google Scholar : PubMed/NCBI
|
